Independent Grants for Learning & Change (IGLC)
Track 2 - Call for Grant Applications (CGA)
Pneumococcal Pneumonia
I. Background
The mission of Pfizer Independent Grants for Learning & Change (IGL&C) is to partner with the global healthcarecommunity to improve patient outcomes in areas of mutual interest through support of measurable learning and change
strategies. “Independent” means that the projects funded by Pfizer are the full responsibility of the recipientorganization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and theimpact of the projects in order to share them publicly.
Through this CGA we encourage organizations to submit grant requests that, if funded, will support education in aspecific disease state, therapeutic area, or broader area of educational need.
When a CGA is issued, it is posted on the IGL&C website (www.pfizer.com/independentgrants) in the Grants Process
section and is sent via e-mail to all registered users in our grants system. Some CGAs may also be posted on thewebsites of other relevant organizations.
II. Eligibility
Geographic Scope:
Applicant Eligibility
Criteria:JapanThe following may apply: medical, dental, nursing, allied health, and/orpharmacy professional schools; healthcare institutions (both large and small);professional associations and medical societies; medical education companies;
and other entities with a mission related to healthcare professional education
and/or healthcare improvement.
More information on organizations eligible to apply directly for a grant can befound athttp://www.pfizer.com/files/IGLC_OrganizationEligibility_effJuly2015.pdf.
Collaborations within institutions (e.g., between departments and/or interprofessional), as well as between different
institutions/organizations/associations, are encouraged. All partners must havea relevant role, and the requesting organization must have a leadership role.

III. Requirements
Date CGA Issued:
Clinical Area:
Specific Area of Interestfor this CGA:

April 25, 2016
Pneumococcal Pneumonia
The intent of this CGA is to encourage organizations to submit applications forindependent educational grants to provide programing targeted to healthcare
providers caring for patients 65 and over. Specifically, programs should focus on
increasing the awareness of this patient population’s higher risk forpneumococcal disease as well as the importance of pneumococcal vaccination
to reduce the burden of pneumococcal disease.
While programing targeted at addressing knowledge gaps may involve livesessions, efforts should be made to encourage interaction and provide
opportunities to extend learning opportunities beyond the live setting. In
addition to live programs, technology-enabled distance learning with facilitatedinteractive components, online courses, and other enduring materials may also
be proposed.
More information on principals of learning and behavior change for healthprofessionals can be found atwww.pfizer.com/files/HealthProfessionalsLearningandBehaviorChange_AFewPr
inciples.pdf.

Expected Approximate
Monetary Range ofGrant Applications:

Key Dates:

Individual projects requesting up to $100,000 will be considered. The total
available budget related to this CGA is $400,000.
The grant amount Pfizer will be prepared to fund will depend upon theevaluation of the proposal and costs involved and will be stated clearly in theapproval notification.
CGA release date: April 25, 2016
Grant application due date: June 6, 2016
Please note the deadline is midnight Japan Standard Time .
Anticipated Grant Award Notification Date: July 18, 2016
Grants distributed following execution of fully signed Letter of Agreement
Period of Performance: August 2016 to August 2018 (projects may be shorter;
24 month project maximum)

2

How to Submit:

Please go to the website at www.pfizer.com/independentgrants and click on
the button “Go to the Grant System.” Registered users should select theappropriate link under Track 2 – Knowledge Gap
If this is your first time visiting this site you will be prompted to take theEligibility Quiz to determine the type of support you are seeking. Please ensure
you identify yourself as a first-time user.
Select the following Educational Area: CGA- Pneumococcal Pneumonia-Japan
Requirements for submission:
Complete all required sections of the online application and upload thecompleted CGA template (see Appendix).

Questions:If you encounter any technical difficulties with the website, please click the“Need Support?” link at the bottom of the page
If you have questions regarding this CGA, please direct them in writing to, Derek
Warnick at (derek.warnick@pfizer.com) with the subject line “CGAPneumococcal Pneumonia-Japan.”
We have created a Question & Answer document on our website atwww.pfizer.com/files/ IGLC_CGAPneumococcalPneumonia_Japan_FAQ.pdf. So
that everyone can benefit from these questions and answers, it will be updated
weekly (Monday) to include any new questions received.

Mechanism by which
Applicants will beNotified:

All applicants will be notified via email by the dates noted above.
Applicants may be asked for additional clarification or to make a summary
presentation during the review period.

IV. Terms and Conditions
1. This CGA does not commit Pfizer or its partners to award a grant or a grant of any particular size if one isawarded, nor to pay any costs incurred in the preparation of a response to this request.
2. Pfizer reserves the right to accept or reject any or all applications received as a result of this request, or to cancel
this CGA in part or in its entirety, if it determines it is in the best interest of Pfizer to do so.
3. For compliance reasons and in fairness to all applicants, all communications about the CGA must comeexclusively to Pfizer IGL&C. Failure to comply will disqualify applicants.
4. Consistent with its commitment to openness and transparency, Pfizer reports education grants provided tomedical, scientific, and patient organizations in the United States. Pfizer reserves the right to announce thedetails of successful grant application(s) by whatever means insures transparency, such as on the Pfizer website,
in presentations, and/or in other public media.
5. Pfizer reserves the right to share with organizations that may be interested in contacting you for further
information (e.g., possible collaborations) the title of your proposed project and the name, address, telephone
number, and e-mail address of the applicant from the requesting organization.

3

6. To comply with 42 U.S.C. § 1320a-7h and 42 C.F.R. §§ 403.900-.914 (the Sunshine Act), Provider (sponsor) must
provide to Pfizer specific information for the U.S.-licensed physicians and U.S. teaching hospitals (“CoveredRecipients,” as defined by applicable law) to whom Provider (sponsor) furnished payments or other transfers ofvalue from the original independent grant awarded by Pfizer. Those payments or transfers-of-value include
compensation, reimbursement for expenses, and meals provided to faculty (planners, speakers, investigators,project leads, etc.) and “items of value” (items that possess a discernable value on the open market, such astextbooks) provided to faculty and participants, if those faculty and/or participants meet the definition ofCovered Recipient. Provider (sponsor) must submit the required information during the reconciliation process orearlier, upon Pfizer’s request, so Pfizer can meet Sunshine Act reporting commitments. Be advised that Pfizer
will not make any payments to any individuals; grant funding shall be paid directly to Provider (sponsor).
7. No portion of a Pfizer independent grant may be used for food and/or beverages for learners and/orparticipants in any capacity. Provider (sponsor) will be required to certify during the reconciliation process
and/or the periodic collection of Sunshine reporting that funds were not used for food and/or beverages forlearners and/or participants.
8. In the performance of all activities related to an independent grant, the Provider (sponsor) and all participants
must comply with all applicable Global Trade Control Laws. “Global Trade Control Laws” include, but are notlimited to, U.S. Export Administration Regulations; the International Traffic in Arms Regulations; EU export
controls on dual-use goods and technology; Financial Sanctions Laws and Restrictive Measures imposed within
the framework of the CFSP - Treaty on European Union; and the economic sanctions rules and regulations
administered by the U.S. Treasury Department's Office of Foreign Assets Control.
Appendix: CGA Grant Submission Template
Grant Applications should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit
exclusive of references. Please include the following:
A. Title
B. Organizational Detail: Describe the attributes of the institutions/organizations that will support and facilitate theexecution of the project, the leadership of the proposed project, and the specific role of each partner in theproposed project.
C. Goal: Briefly state the overall goal of the project.
D. Objectives: List the objectives you plan to meet with your project, in terms of learning and expected outcomes.
E. Assessment of Need: Include a quantitative baseline data summary, initial metrics, or a project starting point(please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your targetarea.
F. Target Learner Audience: Describe the primary audience(s) targeted for this project. Indicate whom you believe
will directly benefit from the project outcomes. Describe the overall population size as well as the size of yoursample population.
G. Project Design and Methods: Describe the planned project, the educational approach, and the way the planned
methods address the established need.
H. Innovation: Explain what measures you have taken to assure that this project idea is original and does not
duplicate other projects or materials already developed. Describe how this project builds upon existing work,
pilot projects, or ongoing projects developed either by your institution or other institutions related to thisproject.
I. Outcomes Evaluation: In terms of the metrics used for the needs assessment, describe how you will determine if
the gap was addressed for the target group. Identify the sources of data you anticipate using to make thedetermination. Describe how you expect to collect and analyze the data. Explain the method used to control forother factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify theamount of change expected from this project in terms of your target audience. Describe how you will determine
if the target audience was fully engaged in the project.

4J.

Dissemination Plan: Describe how the project may have extended benefit beyond the grant. Will the teachingmaterials be made available to others to use? Will there be tools or resources that are made publicly available
beyond the initial project. Describe how the project outcomes might be broadly disseminated.
K. Timeline
L. Additional Information: If there is any additional information you feel Pfizer should be aware of concerning theimportance of this project, please summarize it in within the page limitations.
M. References (outside the 15-page limit)• There is no designated format for references
N. Budget (See template available in application)• While estimating your budget please keep the following items in mind:• Grants awarded by IGLC cannot be used to purchase therapeutic agents (prescription or nonprescription).
• Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for projects.
• A separate Excel file should be uploaded. This does not count toward the page limit.
• An example of the budget template can be found here:
http://cybergrants.com/pfizer/docs/KnowledgeGapBudgetTemplate2015.xls• At the conclusion of your program, a reconciliation of expenses is required using theoriginal budget file submitted.

Grant Applications should be single-spaced using Calibri 12-point font and 1-inch margins. There is a 15-page limitexclusive of references. If extensive, references may be included on 1-2 additional pages.

5